Loading…
Based on limited metadata available, USARxMedicine received an FDA Warning Letter on October 1, 2020, regarding drug products. Without access to the full letter text or specific subject line, the precise nature of the violations cannot be determined from the metadata provided. The warning falls under FDA's drug regulatory authority, though the specific issuing office is not identified in the available information. To understand the actual compliance issues and required corrective actions, review of the complete Warning Letter would be necessary.